Clinical and spirometric alterations in Duchenne muscular dystrophy

被引:0
|
作者
Andrada, LE [1 ]
DeVito, EL [1 ]
机构
[1] UNIV BUENOS AIRES, FAC MED, INST INVEST MED ALFREDO LANARI, RA-1053 BUENOS AIRES, DF, ARGENTINA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 36 patients with Duchenne muscular dystrophy we studied the growth pattern, the type and severity of the spirometric abnormalities, the evolution of the Motor Functional Class (MFC), the infectious complications and treatments. Their age ranged from 6 to 19 years and the MFC was from 1 to 9. Regarding height, up to 12 years we verified a slope of 5.69 +/- 0.58 cm/year (r 0.872 p < 0.001) and a posterior detention was observed. Of the 36 patients, 24 were below the percentile 5. The restrictive disorder prevailed. The forced Vital capacity (FVC) expressed in % of the theoretical Value showed a lineal fall with age, with a negative correlation (r 0.51, p < 0.01) of - 3.5 +/- 0.83%/year. The deterioration of the MFC was marked starting from 6 years; with a slope of 0.84 +/- 0,14 points between 6 to 12 years (r 0.73 p x 0.001). Up to 14 years, the slope was 0.212 +/- 0.084 (r 0.49, p < 0,05). Patients older than 14 years had reached a greater CFM of 7; starting from this MFC a progressive fall of the VC was observed with a slope of - 15.29 +/- 3.39% of CVF/CF (r 0.56, p < 0.001). Nine patients with respiratory infections were documented. Four were pneumonia and 3 of them required mechanical ventilation and died. Only 50% of the patients accepted rehabilitating treatment. Four patients accepted surgery of the alterations of the feet while the patients with deformation of the column underwent spinal stabilization.
引用
收藏
页码:463 / 471
页数:9
相关论文
共 50 条
  • [31] Improving clinical trial design for Duchenne muscular dystrophy
    Merlini, Luciano
    Sabatelli, Patrizia
    BMC NEUROLOGY, 2015, 15
  • [32] Clinical management of Duchenne muscular dystrophy: the state of the art
    Messina, Sonia
    Vita, Gian Luca
    NEUROLOGICAL SCIENCES, 2018, 39 (11) : 1837 - 1845
  • [33] Duchenne muscular dystrophy: clinical trials and emerging tribulations
    Shieh, Perry B.
    CURRENT OPINION IN NEUROLOGY, 2015, 28 (05) : 542 - 546
  • [34] NEW CLINICAL SIGN IN DUCHENNE MUSCULAR-DYSTROPHY
    PRADHAN, S
    PEDIATRIC NEUROLOGY, 1994, 11 (04) : 298 - 300
  • [35] HEIGHT AND CLINICAL COURSE OF DUCHENNE MUSCULAR-DYSTROPHY
    COAKLEY, JH
    GRIFFITHS, RD
    EDWARDS, RHT
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1989, 32 (04): : 552 - 552
  • [36] Clinical utility of serum biomarkers in Duchenne muscular dystrophy
    Yetrib Hathout
    Haeri Seol
    Meng Hsuan J. Han
    Aiping Zhang
    Kristy J. Brown
    Eric P. Hoffman
    Clinical Proteomics, 2016, 13
  • [37] Clinical pulmonary function testing in Duchenne muscular dystrophy
    Mayer, Oscar Henry
    PAEDIATRIC RESPIRATORY REVIEWS, 2019, 30 : 9 - 12
  • [38] Clinical utility of serum biomarkers in Duchenne muscular dystrophy
    Hathout, Yetrib
    Seol, Haeri
    Han, Meng Hsuan J.
    Zhang, Aiping
    Brown, Kristy J.
    Hoffman, Eric P.
    CLINICAL PROTEOMICS, 2016, 13
  • [39] CLINICAL MANIFESTATIONS IN 2 CARRIERS OF DUCHENNE MUSCULAR DYSTROPHY
    EMERY, AEH
    LANCET, 1963, 1 (729): : 1126 - +
  • [40] Clinical trials of exon skipping in Duchenne muscular dystrophy
    Mendell, Jerry R.
    Sahenk, Zarife
    Rodino-Klapac, Louise R.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (09): : 683 - 690